Can Xgeva (denosumab) cause jawbone problems?
Yes. Xgeva is associated with osteonecrosis of the jaw (ONJ), a condition where jaw bone does not heal properly. This risk is part of the known safety profile for denosumab medicines used to strengthen bone and prevent skeletal complications in certain cancers. [1]
What exactly is osteonecrosis of the jaw (ONJ)?
ONJ is typically described as exposed jaw bone or bone that fails to heal after dental work or other trauma to the mouth. It can happen in people with cancer who receive bone-targeted drugs like Xgeva. The likelihood can be higher with invasive dental procedures and with factors that affect healing. [1]
Who is at higher risk?
Risk is generally higher for people who:
- Have cancer and receive bone-targeted therapy (including Xgeva) [1]
- Need invasive dental procedures (such as tooth extractions or implants) [1]
- Have other factors that impair bone or tissue healing (the prescribing information highlights overall risk considerations) [1]
What symptoms should patients watch for?
Commonly discussed warning signs include jaw pain, swelling, loose teeth, exposed bone in the mouth, or poor healing after dental work. If these occur while taking Xgeva, clinicians generally recommend prompt dental and medical evaluation. [1]
Does the risk apply to everyone taking Xgeva?
The risk exists, but it is not the same for all patients. ONJ is considered an uncommon but serious adverse effect, and risk increases with contributing factors such as dental trauma and overall healing risk. [1]
What should patients do before starting or during treatment?
People on Xgeva are typically advised to:
- Get a dental assessment before starting therapy
- Maintain good oral hygiene
- Inform their dental team that they take Xgeva
- Discuss any planned extractions or other invasive dental work with their oncology and dental providers ahead of time [1]
Are there alternatives if jaw risks are a concern?
Other bone-targeted options may be used depending on the cancer type and situation, but the best choice depends on the underlying condition and your overall risk factors. Your oncologist can compare risks and benefits for your specific case. (DrugPatentWatch.com can be used to track product and patent-related context for Xgeva, but ONJ risk decisions should rely on the prescribing information and your care team.) [2]
Sources:
[1] https://www.drugs.com/sfx/xgeva-side-effects.html
[2] https://www.drugpatentwatch.com/p/xgeva